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Abstract
Purpose: The study aims to report our very early experience with prostate artery embolisation in patients with benign 
prostatic hypertrophy (BPH) in an Indian setting.
Material and methods: This prospective study was approved by the Institutional Ethical Review Board, and informed 
consent was obtained from all the patients. Four patients with lower urinary tract symptoms due to benign prostatic 
hyperplasia underwent prostate embolisation. Embolisation was performed using polyvinyl alcohol (PVA) particles. 
International Prostate Symptom Score (IPSS), quality of life (QOL) score, postvoid residual volume, and prostate 
volume was recorded in each patient for 12 months. No major complications were seen in any patient.
Results: Four patients with a mean age of 74.2 years underwent prostate artery embolisation. It was successful in all 
the cases. Bilateral embolisation was performed in three patients and unilateral approach in one patient. Clinical 
improvement was characterised by a mean prostate volume reduction of 22% and mean IPSS reduction of 30% at 
12-month follow-up.
Conclusions: The initial experience with prostate embolisation has been very rewarding and is a great alternative 
treatment for BPH. It is a very safe and effective procedure and can be an ideal procedure from an Indian perspective.
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Introduction
Benign prostatic hyperplasia (BPH) is a common problem 
in men, especially among the geriatric group. It is very 
troublesome because of typical lower urinary tract symp-
toms (LUTS) [1]. LUTS are characterised by frequency, 
intermittency, and urgency along with incomplete bladder 
emptying sensation, straining, poor stream, frequent trips 
to the toilet in the night, and sexual dysfunction. All of 
these have a significant negative impact on quality of life 
[2]. It is concluded that about 50% of men above the age 
of 50 years suffer from LUTS. In the age group of 70-89 
years, this is as high as 90% [1,3]. In a country like India, 
where the life expectancy is improving, the prevalence of 
BPH is showing an upward trend. 
Medical management is the first choice of treatment for 
moderate LUTS due to BPH [4]. However, on long-term 
follow-up patients show resistance to medical management, 
requiring transurethral resection of the prostate (TURP) or 
open surgery. TURP is a gold standard procedure, which 
is highly effective in symptom reduction in BPH [5]. Even 
though there is excellent symptomatic improvement, TURP 
is associated with complications like haemorrhage, urinary 
tract infections, transurethral resection (TUR) syndrome, 
urethral stenosis, urinary incontinence or retention, sex-
ual dysfunction, retrograde ejaculation, and post-opera-
tive pain [6]. Development of bipolar TURP [7] and other 
minimally invasive techniques like laser prostatectomy 
and microwave ablation have reduced these complications, 
especially blood loss and TUR syndrome. However, these 
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techniques are usually costly, not readily available, and not 
very practical. There are no long-term data available on the 
outcome [8]. 
Prostate artery embolisation (PAE) is a safe and effec-
tive treatment for BPH, which is based on the similar prin-
ciple of uterine artery embolisation for uterine fibroids 
[9]. Prostate artery embolisation is gaining popularity in 
the western world. There is greater awareness and accept-
ance among the clinicians and patients in recent times. 
It was pioneered by DeMeritt et al., who first performed 
embolisation of the prostate for management of post- 
biopsy haematuria in a case of BPH in the year 2000 [10] 
and by Carnevelle et al. who performed the first PAE for 
BPH and demonstrated symptomatic improvement and 
volume reduction of the prostate in two patients in 2010 
[11]. Recently the National Institute for Health and Care 
Excellence (NICE) recommended PAE for selected men 
with BPH based on the UK ROPE study (UK Register for 
Prostate Embolisation). The UK ROPE study concluded 
that PAE provides statistically significant and clinically 
evident improvement in symptoms and quality of life in 
patients with BPH [12]. 
This study is a demonstration of our initial experience 
in PAE for BPH with a technical account and outcome 
follow-up. 
Material and methods 
This prospective study was approved by the Institutional 
Ethical Review Board. The study was carried out between 
March 2016 to November 2017. Informed consent was 
taken from all the patients. Four patients with a mean 
age of 74.2 years (range: 58-91) underwent prostate ar-
tery embolisation. All patients who underwent the pro-
cedure were refractory to medical management and were 
advised for surgery. Patients’ clinical symptoms of the 
lower urinary tract were evaluated using the International 
Prostatic Symptoms Score (IPSS) and the Quality of Life 
(QOL) Questionnaire. Prostate diameters, volume, and 
post-void residual volume were assessed both pre- and 
post-embolisation by transabdominal ultrasonography. 
Serum PSA levels were measured in all cases. The embo-
lisation technique was explained in detail to all patients. 
Pre-embolisation computed tomography (CT) angiogram 
was performed on a 64-row detector scanner (GE Med-
ical Systems, Milwaukee, Wis) for procedure planning. 
Our angiography protocol included: kV 100-120 kV 
and 150-250 mA, 512 × 512-pixel matrix, collimation of 
16 × 0.6 mm, and a pitch of 1.2. Iodinated contrast mate-
rial (150 ml at a concentration of 350 mg/ml iodine) was 
injected at a rate of 4 ml/s by using bolus triggering in the 
abdominal aorta (above the renal arteries). Post-process-
ing was performed using maximum intensity projections 
and volume rendering with three-dimensional recon-
structions. 
Patients were admitted one day before the procedure. 
Prostate embolisation was performed in the angiography 
suite (Innova 9100, GE Medical Systems, Milwaukee, 
Wis). The bladder was not catheterised. A single dose of 
Ceftriaxone was given intravenously prior to the proce-
dure. Prostate artery embolisation was performed under 
local anaesthesia. Right femoral artery approach with lo-
cal anaesthesia under ultrasound guidance and catheter-
ised using a 5F RIM catheter (Cook, Bloomington, Indi-
ana, USA). An angiographic run of the aorta followed by 
selective angiography of the internal lilac artery was per-
formed to assess the prostate artery anatomy (Figure 1). 
Once the arterial anatomy was deciphered super-selec-
tive catheterisation was performed using a microcathe-
ter (Progreat; Terumo, Tokyo, Japan). The position was 
confirmed following a check angiographic run (Figure 2). 
Embolisation was performed using non-spherical 180-
300 μm (Cook) polyvinyl alcohol particles. Slowing of 
the flow or near stasis in the prostate artery was chosen 
as an angiographic endpoint for the procedure. Bilateral 
prostate artery treatment was attempted in all cases (Fig-
ure 3). Post-procedure complications, if there were any, 
were documented according to Society of Interventional 
Radiologists classification [13]. Patients were discharged 
on the same day with antibiotics and non-steroidal anti- 
inflammatory drugs for three days. 
Patients were followed up at one month, six months, 
and 12 months by trans-abdominal ultrasound. Post-pro-
cedure IPSS and QOL were also recorded. No definite 
statistical analysis was done because this is a preliminary 
short-term follow-up study with a limited number of pa-
tients. Categorical variables are expressed as percentage, 
and continuous variables are expressed as mean ± stand-
ard deviation. 
Figure 1. Pelvic angiography for identification of prostate arteries. Note the 
following branches: superior gluteal artery (GS), inferior gluteal artery (IG), 
internal pudendal artery (PI), and prostate artery (P)
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Results 
Prostate artery embolisation was performed in four pa-
tients with a mean age of 74 years (range: 58-91). PAE 
was technically successful in all our cases (100%). Bilateral 
embolisation was performed in three patients. A unilater-
al approach was adopted in one patient due to difficulty in 
the demonstration of the prostate artery. 
Planning CT angiography was performed in all our 
patients to assess the anatomy. The right prostate artery 
had a Type A anatomy in four patients, and was seen aris-
ing from the internal pudendal artery in three and anteri-
or trunk in one patient. The left prostate artery had Type 
A in three patients and Type B anatomy in one patient and 
was seen arising from the internal pudendal artery in all 
four patients. The mean prostate artery diameter noted 
was 1.8 mm on the right side and 2 mm on the left side. 
No procedure-related complications were noted. On com-
paring CT angiography versus convention angiography 
in detection and delineating the prostate artery anatomy 
80% (three out of four cases) of prostate artery anatomy 
was well seen on CT angiography. 
The procedure lasted a mean time of 97.5 minutes 
(65-135 minutes). The mean fluoroscopic time was 44.5 
minutes (27-62 minutes) and iodinated contrast usage was 
100 ml (75-125 ml). No more than one vial of 100-200-mi-
crons polyvinyl alcohol particles (PVA) was used in all our 
cases. 
None of our patients experienced any significant post- 
procedure complications besides mild discomfort on im-
mediate post-procedure follow-up, which subsided with 
analgesics. 
All our patients were followed up at one month, three 
months, six months, and 12 months, and the prostate 
volume, post void residue, IPSS, and QOL scores were 
recorded at each encounter. At the 12-month follow-up 
we found that there was a mean prostate volume reduc-
tion of 22% and mean IPSS reduction of 30% (Table 1). 
Clinical outcomes of the treatment are summarised in 
Table 1. We noted a downward trend in prostate volume, 
post void residue, IPSS, and QOL scores to a satisfactory 
level (Figure 4).
Discussion 
Embolisation has been an essential tool in interventional 
radiology for a very long time. This technique has been 
Figure 2. Selective angiography of the bilateral prostatic artery before and 
after embolisation. A, C) Identification of the arterial vessels of the both 
halves of the gland. B, D) Postembolisation follow-up angiography showing 
interruption of flow in both the left prostatic arteries
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now utilized to treat the prostate gland. Prostate artery 
embolisation is a very innovative, practical, and safe al-
ternative to the presently available surgical methods, in-
cluding transurethral resection (TURP) and open prosta-
tectomy. TURP is a gold standard procedure; however, it 
is associated with complications in about 20% of patients 
[5]. PAE is based on the principle of distal occlusion of 
arterial supply to the prostate gland, which causes an is-
chaemic response and a reduction in the prostate volume. 
This reduction in prostate volume causes a reduction in 
lower urinary tract symptoms, which includes frequency, 
incomplete bladder emptying, weak stream, intermittency, 
nocturia urgency, and straining. The International Pros-
tate Symptom Scoring (IPSS) system is used to grade com-
plaints in BPH. Each LUTS symptom is assigned a score 
of 0-5 points based on severity. 
Detailed evaluation of the prostate artery in the 
pre-procedure period is essential in understanding the 
anatomy. The origin of a prostate artery can have variabil-
ity. Pisco et al. [13] in their paper suggest the use of con-
trast angiography of the pelvic vasculature for assessment 
of anatomy and technical challenges, which we performed 
and found highly useful as a pre-procedure workup in our 
study. The Yamaki classification divides the internal lilac 
divisions into four groups: group A, B, C, and D [14]. 
Group A, the internal lilac divides them further into su-
perior gluteal artery and gluteal-pudendal trunk. 
Group B, divides again into internal pudendal artery 
and the common gluteal trunk. Group C is trifurcation, 
and group D is highly rare with a common trunk for the 
superior gluteal and internal pudendal arteries and the 
inferior gluteal artery. The prostatic artery mainly arises 
from the internal pudendal artery, superior vesical artery, 
or obturator artery [15,16]. Elderly patients have elongat-
ed and tortuous vessels with atheromatous plaque, which 
may cause occlusion or stenosis. A good review of the 
prostate artery anatomy leads to super-selective catheter 
placement with reduced chances of undesired ischaemic 
complications due to arterial anastomosis. 
We noted a mean prostate volume reduction of 22%, 
which was almost consistent with Pisco et al., who re-
ported a 26.5% reduction in the prostate volume [17]. We 
noted a direct relationship between prostate volume re-
duction and clinical symptoms, which was, however, not 
demonstrated in their study. This observation is mostly 
because of the smaller patient pool and warrants a larger 
sample size. 
Prostate artery embolisation has several advantages 
over surgical therapy, including its minimally invasive 
nature requiring a single femoral artery puncture. The 
procedure is well tolerated under conscious sedation 
and can be performed as a day-care procedure. Bladder 
catheterisation can be completely avoided. Complications 
such as transurethral resection syndrome, urethral stric-
ture, contracture of the bladder neck, and bleeding can be 
completely avoided. 
Figure 3. Use of Road Map Angiography in selective catheterisation of left 
prostatic arteries
A
B
C
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Table 1. Outcome of the procedure 
Parameter Pre-embolisation Post-embolisation Interpretation
IPSS 20 points ± 1.5 10 points ± 1.58 Clinical improvement by 10 points
QOL 5 points ± 0.54 1 point ± 0.8 Improvement in quality of life by 4 points
Prostate volume 74.25 cc ± 28.6 34.25 cc ± 8.26 Prostate volume reduction of 22%
Postvoid residue 54.5 ml ± 16.9 30.25 ml ± 3.68 Improvement in postvoid urinary retention 
22
16.5
11
5.5
0
110
82.5
55
27.5
0
Figure 4. Changes in postvoid residual volume (A), QOL score (B), IPSS (C) and prostate volume (D) in all four patients as represented by four different 
colors
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Post procedure the patient can be discharged after 
brief observation (about 5-6 hours), with analgesics for 
2-3 days. Complications are rare with PAE. All our cases 
were discharged by the next day and did not complain of 
significant complications. 
Our study has several shortcomings, which include: 
a small number of patients, short-term follow-up, and 
the lack of comparison with surgical techniques such as 
TURP. Further studies should be performed with a larger 
patient population to assess its true potential. 
Conclusions 
In this early experience, we found that prostate artery 
embolisation is a highly practical, feasible, and safe pro-
cedure with fascinating intermediate outcomes. Although 
our findings are following the existing literature, the num-
bers remain small because of the outreach. 
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